		OIP	2005					Page 1 of 1				
Form P	TO-1449	(modified)	Atty. Docket N	Atty. Docket No.		Serial No.						
	5	FEB 2	T TOND	INRP:104US				<u> </u>				
List of P	atents and	d Publications for A	.07/	Applicant George H. You	Applicant							
Info	ORMATIO	N DISCLOSURE SH	George H. 100	George II. 100								
	(Use se	veral sheets if necessary	Filing Date:	Filing Date: December 29, 2003		Group: 1633						
				Patent Document			Other Art					
See Page 1				See Page 1			See Page 1					
7		· ··										
U.S. Patent Documents												
Exam. Init.	Ref. Des.	Document Number	Date	Name (Class	Sub Class	Filing Date of App.				
Foreign Patent Documents												
Exam. Init.	Ref. Des.	Document Number	Date	Country	Country Class		ıb Iss	Translation Yes/No				
Other Art (Including Author, Title, Date Pertinent Pages, Etc.)												
Exam. Init.	Ref. Des.	Citation										
SDP	Cl	"Recombinant DNA Advisory Committee: Recombinant DNA and Gene Transfer," NIH Publisher, pp. 1-2, published on the www at http://www4.od.nih.gov/oba/rac/aboutrdagt.htm. , march 29,										
	C2	"Human genetics in the public interest," Center for Genetics and Society, Center for Genetics and Society, pp. 1-2, http://www.genetics-and-society.org/policies/us/agencies.html , Avj. 28, 2002.										
	C23	Clayman, "Clinical protocol for wild type p53 gene induction in premalignancies of squamous epithelium of the oral cavity via an adenoviral vector," Scientific Abstract, sponsored by Introgen, Inc., submitted January 8, 2001, place of publication NIH Recombinant DNA Advisory Committee meeting March 8, 2001, page 2.										
	C24	Clayman, "Clinical protocol for wild type p53 gene induction in premalignancies of squamous epithelium of the oral cavity via an adenoviral vector," Non-Technical Abstract, sponsored by Introgen, Inc., submitted January 8, 2001, place of publication NIH Recombinant DNA Advisory Committee meeting March 8, 2001, page 3.										
	C95	"Clinical protocol for wild tupe p53 gene induction in premalignancies of squamous epithelium of the oral cavity via an adenoviral vector," Investigator Gary Clayman, Sponsor Introgen Therapeutics, PowerPoint presentation, presented at NIH Recombinant DNA Advisory Committee meeting March 8, 2001.										

25626549.1

Examiner:	Sutt D.	mile	DATE CONSIDERED:	4/12/06	

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.